リウマチ性関節炎患者のTNFAIP3,IRAK1,TLR4遺伝子ポリモルフィズムに関する分析
Zhenboyang Tang1, Lihui Peng1,2, Zixia Zhao1,3
1Department of Rheumatology and Immunology, The Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China.
Immunity, inflammation and disease
|February 13, 2026
まとめ
腫瘍死滅因子α誘発タンパク質3 (TNFAIP3),インタールイキン-1受容体関連キナーゼ1 (IRAK1),およびトール型受容体4 (TLR4) の遺伝的変異は,関節リウマチ症 (RA) 感受性に関連しています. 特定の遺伝子ポリモルフィズムにより,RAのリスクが低下し,他の遺伝子ポリモルフィズムにより,RAリスクが増加します.
科学分野:
- 免疫遺伝学 免疫遺伝学とは
- レウマトロジーの病理学
- 分子生物学は分子生物学である.
背景:
- リウマチ性関節炎 (RA) は,遺伝的および環境的要因の影響を受ける自己免疫疾患です.
- 腫瘍死滅因子α誘発タンパク質3 (TNFAIP3),インタールイキン-1受容体関連キナーゼ1 (IRAK1),およびトール型受容体4 (TLR4) は,免疫経路の重要な遺伝子である.
- これらの遺伝子のポリモルフィズムにより,RAの感受性が変化する可能性があります.
研究 の 目的:
- TNFAIP3,IRAK1,TLR4の特定の遺伝子ポリモルフィズムとRAを発症するリスクとの関連を調査する.
- これらの免疫関連遺伝子の変異が,関節リウマチ症の複雑な病因に寄与するかどうかを判断する.
主な方法:
- TNFAIP3,IRAK1,TLR4の遺伝子ポリモルフィズムのゲノタイプ化は,質量スペクトロメトリを用いて行われました.
- 症例対照試験の設計には,308人のRA患者と310人の健康な対照群が含まれていました.
- 確率比と信頼区間を含む統計的分析が,ゲノタイプとRAリスクとの関連性を評価するために使用されました.
主要な成果:
- 特定のIRAK1 (rs1059703Aアレル) とTNFAIP3 (rs5029930Cアレル,AC遺伝子型) のポリモルフィズムがRAのリスク低下と関連していた.
- 対照的に,TNFAIP3 (rs5029939 C アレル) とTLR4 (rs7873784 C アレル,CG 遺伝子型) のポリモルフィズムは,RAのリスク増加と関連していた.
- これらの発見は,特定の遺伝子変異が,関節リウマチ症の感受性に対して異なる影響を及ぼすことを示しています.
結論:
- TNFAIP3,IRAK1,TLR4の遺伝子ポリモルフィズムは,関節リウマチ症の感受性と有意に関連しています.
- これらの遺伝的変異は,RA発症に寄与する要因の複雑な相互作用において役割を果たします.
- さらなる研究は,RAの病原性におけるこれらのポリモルフィズムの機能的影響を調査することができます.
関連する概念動画
Single Nucleotide Polymorphisms-SNPs
18.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
18.6K
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
752
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
752
Gene Flow
38.1K
Gene flow is the transfer of genes among populations, resulting from either the dispersal of gametes or from the migration of individuals.
38.1K
Gene Families
10.0K
Gene families consist of groups of genes proposed to have originated from a common ancestor. Typically these arise through events in which a gene or genes are mistakenly duplicated during cell division. Unlike their parent genes (which are subject to selection pressure to maintain function), these gene copies do not need to preserve their sequences and may evolve at a relatively faster rate.
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
10.0K
Gene Conversion
10.7K
Other than maintaining genome stability via DNA repair, homologous recombination plays an important role in diversifying the genome. In fact, the recombination of sequences forms the molecular basis of genomic evolution. Random and non-random permutations of genomic sequences create a library of new amalgamated sequences. These newly formed genomes can determine the fitness and survival of cells. In bacteria, homologous and non-homologous types of recombination lead to the evolution of new...
10.7K
Gene Therapy
27.7K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K


